All Releases
August 2010
25/08/10
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology
20/08/10
Additional Phase III Clinical Trial with UrocidinTM Expected to Commence in 2010
June 2010
23/06/10
Bioniche & Trophogen Sign Exclusive Global Veterinary License Agreement for Superagonist Hormone Technology Platform
17/06/10
Bioniche Strengthens its International Patent Portfolio for its MCC & Oligonucleotide Technology Platforms
02/06/10
Bioniche Animal Health Partners with Bayer Australia to Distribute Livestock Product Line
May 2010
17/05/10
Bioniche Recognizes 10th Anniversary of Walkerton, Ontario Water Contamination Tragedy
12/05/10
Bioniche Reports Fiscal 2010 Third Quarter Results
April 2010
19/04/10
Bioniche Receives FedDev Ontario Investment to Support Fermentation Scale-Up for New Vaccine Manufacturing Centre
March 2010
16/03/10
Canadian Cattle Producers Willing to Make Changes to Prevent E. coli O157 Contamination on their Farms
February 2010
12/02/10
Bioniche Achieves Two Additional Milestones Under Licensing Agreement; Endo Takes up Global Rights
10/02/10
Bioniche Reports Fiscal 2010 Second Quarter Results
January 2010
29/01/10
Bioniche E. coli O157 Vaccine Recognized in Prestigious Scientific Journal
November 2009
25/11/09
Bioniche Strengthens the International Patent Portfolio for its MCC Technology Platform
06/11/09
Bioniche Reports Fiscal 2010 First Quarter Results And Achievement of First Milestone Under Licensing Agreement
September 2009
21/09/09
Bioniche Reports Fiscal 2009 Year-End Results
August 2009
24/08/09
Bioniche Phase III Clinical Trial with Urocidin™ Given Continued Green Light by DMC
05/08/09
Bioniche Announces Resignation of its CFO
July 2009
20/07/09
Bioniche Repays Revolving Credit Facility
17/07/09
EconicheTM Vaccine Efficacy Summarized in July Issue of Foodborne Pathogens and Disease
10/07/09
Bioniche Life Sciences Inc. and Endo Pharmaceuticals Inc. Sign Licensing Agreement for UrocidinTM
June 2009
22/06/09
Bioniche Provides a Corporate Update
May 2009
28/05/09
Bioniche Represented at House of Commons Sub-Committee on Food Safety
22/05/09
Bioniche Phase III Clinical Trial with Urocidin™ Progressing Well
06/05/09
Bioniche Reports Fiscal 2009 Third Quarter
April 2009
27/04/09
Bioniche Provides a Corporate Update
March 2009
31/03/09
Bioniche Completes Recruitment in First Phase III Clinical Trial with UrocidinTM
13/03/09
EconicheTM Vaccine Shows 92% Reduction in Colonization of E. coli O157 in Vaccinated Cattle
02/03/09
Bioniche Revolving Credit Facility Maturity Date Amended
February 2009
18/02/09
Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
17/02/09
Bioniche Warrants’ Expiration Date to be Extended
06/02/09
Bioniche Reports Fiscal 2009 Second Quarter
03/02/09
Bioniche Invited to Participate in Canadian Beef Value Chain Roundtable
January 2009
14/01/09
Bioniche Named One of the Top 50 Best Small and Medium Employers in Canada
November 2008
24/11/08
Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile
17/11/08
Update on Bioniche Phase III Clinical Trial in Bladder Cancer
07/11/08
Bioniche Reports Fiscal 2009 First Quarter
October 2008
27/10/08
World’s First Cattle Vaccine to Reduce E. coli O157 Threat Receives Full Licensing Approval in Canada
17/10/08
E. coli O157 Vaccine Efficacy Reinforced by Study Published in Foodborne Pathogens and Disease
September 2008
24/09/08
Canadian Regulator Recognizes Efficacy and Safety of Bioniche E. coli O157 Cattle Vaccine
19/09/08
Bioniche Reports Fiscal 2008 Year-End Results
09/09/08
Bioniche Allows Conversion of Portion of Revolving Credit Facility
August 2008
25/08/08
Bioniche Animal Health Immunotherapy Now Listed as “Organic” for Use in Cattle
18/08/08
Bioniche Phase III Clinical Trial in Bladder Cancer Progressing Well
July 2008
10/07/08
Bioniche Presents E. coli O157:H7 Vaccine Data to World Buiatrics Congress in Budapest, Hungary
June 2008
27/06/08
Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference
25/06/08
Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production
17/06/08
Bioniche Presents E. coli O157:H7 Vaccine Data to International Congress of Medical Microbiology in Serbia.
May 2008
23/05/08
Bioniche Presents Pre-Clinical Research at Two International Conferences
13/05/08
Bioniche Updates re: Mycobacterial Cell Wall Technology Platform
09/05/08
Bioniche Reports Fiscal 2008 Third Quarter
April 2008
21/04/08
Bioniche Appoints U.S. President of Food Safety
18/04/08
Bioniche Reports the Passing of its Board Chair
March 2008
27/03/08
Bioniche Converts a Portion of its Debt to Equity
04/03/08
Bioniche Receives Fast track Designation for First-Line Bladder Cancer Therapy
February 2008
13/02/08
Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin™
12/02/08
Bioniche Reports Fiscal 2008 Second Quarter
08/02/08
Bioniche Receives $5 Million Capital Financing Support to Scale-up E. coli O157:H7 Vaccine Production
05/02/08
USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
December 2007
21/12/07
Bioniche Amends Terms of Convertible Debt with Laurus Master Funds
20/12/07
Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario
18/12/07
Bioniche Receives $10 Million of Provincial Government Support to Scale-up Vaccine Production in Ontario
17/12/07
Announcement Planned by Ontario Ministry of Economic Development and Trade
04/12/07
Bioniche Recognized as One of the Top 10 Life Science Companies in Canada
November 2007
15/11/07
Bioniche Presents at Annual Convention of Canadian Association of Fairs & Exhibitions
13/11/07
Journal of Food Protection Publishes Two Articles on E. coli O157:H7 Vaccine Efficacy
09/11/07
Bioniche Reports Fiscal 2008 First Quarter
06/11/07
Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference
October 2007
05/10/07
Bioniche Receives Comment from USDA on a Field Trial for E. coli O157:H7 Cattle Vaccine
05/10/07
Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial
04/10/07
Bioniche to Present at BioContact Quebec 2007
September 2007
27/09/07
Bioniche Food Safety Vaccine Receives Global Top Honours in Industry Excellence Awards
26/09/07
Bioniche Reports Fiscal 2007 Year-End Results
24/09/07
Beef Cattle Vaccinated Against E. coli O157:H7
21/09/07
Bioniche Reports Year-End Fiscal 2007 Results
10/09/07
Bioniche Reaches Special Protocol Assessment Agreement with U.S. FDA for Phase III Comparative Bladder Cancer Trial
07/09/07
Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
06/09/07
Bioniche Responds to Australian Equine Influenza Outbreak
August 2007
24/08/07
Bioniche Ships First Order of E. coli O157:H7 Cattle Vaccine
16/08/07
Bioniche Provides Update on Refractory Bladder Cancer Trial
July 2007
30/07/07
Bioniche Lists Warrants in Connection with March 7, 2007 Offering of Units
19/07/07
Bioniche Appoints New Animal Health and Food Safety Leadership Team
18/07/07
Bioniche Appoints New Director to its Board
June 2007
06/06/07
Solidarity Fund QFL Converting 25% of its Preferred Shares in Bioniche Life Sciences
May 2007
22/05/07
Data Shows Bioniche Proprietary MCC Technology Effective in Inducing Anticancer Activity in 3 Hours
04/05/07
Bioniche Reports Third Quarter Results for Fiscal 2007
01/05/07
Bioniche E. coli O157:H7 Vaccine Discussed at 4th International Conference on Vaccines for Enteric Diseases
April 2007
18/04/07
Bioniche Eliminates Convertible Debt with Laurus Master Funds
16/04/07
Bioniche Presents Additional Data on the Anticancer Activity of MCC Against Peritoneal Carcinomatosis
03/04/07
Non-Antibiotic Treatment for Equine Endometritis Study Data Published in International Peer-Reviewed Journal
March 2007
30/03/07
Bioniche Recognized with Québec Biotechnology Award
29/03/07
Bioniche and Technology Partnerships Canada Amend Agreement on MCC Research Project
13/03/07
Bioniche Closes C$17.5 Million Equity Financing
02/03/07
Bioniche Files Final Short-Form Prospectus for Offering of Units
February 2007
09/02/07
Bioniche Files Preliminary Short-Form Prospectus for Offering of Units
02/02/07
Bioniche Reports Second Quarter Results for Fiscal 2007
January 2007
12/01/07
Bioniche Further Pays Down Debt with Laurus Master Funds
10/01/07
Canadian Research Collaboration Produces World's First Food Safety Vaccine: Against E. coli 0157:H7
December 2006
22/12/06
Bioniche E. coli O157:H7 Cattle Vaccine Authorized for Field Use in Canada
22/12/06
Bioniche Further Pays Down Debt
15/12/06
Bioniche Life Sciences Experiences Significant Trading Volume Following Progress Update on E. coli O157:H7 Cattle Vaccine Canadian Regulatory Status
08/12/06
Bioniche Life Sciences Clears Path for Priority Review of its E. coli O157:H7 Cattle Vaccine in Canada
08/12/06
Bioniche Completes Sale of Two Remaining Assets Associated with Irish Pharma Group
06/12/06
Bioniche Life Sciences' E. coli O157:H7 Cattle Vaccine Data Presented at Two International Symposia
November 2006
10/11/06
Bioniche Reports First Quarter Results for Fiscal 2007
08/11/06
First Patient Treated in Bioniche Phase III Refractory Bladder Cancer Trial
07/11/06
Bioniche Plans to Liquidate Two Remaining Assets Associated with Irish Pharma Group
02/11/06
Bioniche Expands Patent Portfolio with Three New Patents
October 2006
31/10/06
Bioniche to Present at Rodman & Renshaw 8th Annual Healthcare Conference
02/10/06
Bioniche Board Approves a Shareholders Rights Plan
September 2006
29/09/06
Bioniche Life Sciences Inc. Re-Files its 2005 MD&A and Certificates
28/09/06
Bioniche Reports Fiscal Year-End Results
22/09/06
Update for Bioniche Year-End Fiscal 2006 Call/Cast Per CNW Group
15/09/06
New Date for Bioniche Year-End Fiscal 2006 Call/Cast
11/09/06
Bioniche Reports Year-End Fiscal 2006 Results
June 2006
29/06/06
Bioniche Presents Additional Data on Anticancer Activity of Mycobacterial Cell Wall-DNA Complex (MCC) Against Human Bladder Cancer Cells
27/06/06
Cameron Groome Joins Bioniche as Executive Vice-President, Corporate & Strategic Development
05/06/06
Counterfeit Product Linked to Death of Ontario Horse
May 2006
24/05/06
Mycobacterial Cell Wall-DNA Complex (MCC) Demonstrates Anticancer Activity in an Animal Model of Colon Cancer
23/05/06
Bioniche Closes Sale of its Proprietary Cystitis Product
09/05/06
Bioniche Third Quarter Results Correction
05/05/06
Bioniche Reports Third Quarter Results for Fiscal 2006
04/05/06
U.S. FDA Grants Fast Track Designation for Bioniche Bladder Cancer Product
03/05/06
Bioniche Sells Proprietary Cystitis Product for $10 Million Cdn.
02/05/06
Media Advisory - Bioniche Reports Third Quarter Results for Fiscal 2006
April 2006
03/04/06
Bioniche Receives FDA Approval to Proceed with Phase III Bladder Cancer Trials
March 2006
27/03/06
Bioniche to Host Bladder Cancer Roundtable
22/03/06
Updates on MCC Phase III Bladder Cancer Study and E. coli O157:H7 Cattle Vaccine Regulatory Progress
13/03/06
Bioniche Granted First Major Composition Patent for Oligonucleotide Technology
February 2006
08/02/06
Bioniche Reports Second Quarter Results for Fiscal 2006
07/02/06
U.S. FDA Accepts Part One of Bioniche Program for Phase III Clinical Trials with MCC for Bladder Cancer
02/02/06
Media Advisory - Bioniche Reports Second Quarter Results for Fiscal 2006
01/02/06
Bioniche and RoundTable Healthcare Partners Close Sale of Bioniche Pharma Group Ltd.
January 2006
12/01/06
Bioniche Signs Definitive Purchase Agreement for Sale of Pharma Group to RoundTable Healthcare Partners
December 2005
09/12/05
Bioniche Completes Private Financing
November 2005
04/11/05
Bioniche Reports First Quarter Results for Fiscal 2006
01/11/05
Bioniche Annual Meeting Web Cast and First Quarter Results for Fiscal 2006
October 2005
28/10/05
Bioniche Clarifies Terms of Pharma Group Sale and Private Placement
18/10/05
Bioniche Pharma Group and AngioDynamics Sign Exclusive Distribution Agreement for Sotradecol(R) Injection
14/10/05
Bioniche Discussing Potential Private Placement
05/10/05
Bioniche and ICC Private Equity Fund Agree to Sell Bioniche Pharma Group to RoundTable Healthcare Partners
04/10/05
Bioniche Retains Blackmont Capital to Assist in the Sale of its Pharma Business Unit
September 2005
29/09/05
Bioniche Reports Fiscal Year-End Results and Unveils Plans to Convert Business Unit into Cash
26/09/05
Bioniche in Good Standing with Technology Partnerships Canada (TPC)
20/09/05
New Date/Time for Bioniche Fiscal 2005 Year-End Call/Cast
15/09/05
Bioniche Reports Year-End Fiscal 2005 Results
July 2005
14/07/05
Bioniche Launches Sotradecol® Injection for Varicose Veins in U.S. Market
12/07/05
Bioniche Reports Positive News from BetacTM Product Recall Investigation
June 2005
20/06/05
Bioniche Life Sciences Retains GCI Group as Strategic Investor Relations Counsel
17/06/05
Bioniche Issues Recall of BetacTM
16/06/05
Bioniche Presents Data on Anticancer Activity of Mycobacterial Cell Wall-DNA Complex (MCC) Against Peritoneal (Colon) Cancer
13/06/05
Bioniche Appoints New Chief Medical Officer to Advance Clinical Trials
03/06/05
New Studies Demonstrate Immunomodulatory Activity of Bioniche Technology in Dogs
03/06/05
New Studies Demonstrate Immunomodulatory Activity of Bioniche Technology in Dogs
01/06/05
Bioniche Pharma Group and Grünenthal Sign Exclusive Agreement for Distribution of Suplasyn®
May 2005
26/05/05
Bioniche Granted European Patent for Mycobacterial Cell Wall-DNA Complex (MCC) as Prostate Cancer Treatment
24/05/05
Bioniche Mycobacterial Cell Wall Extract (MCWE) Granted New Patent for Production Performance in Animals
17/05/05
Bioniche Granted Additional Patent for Mycobacterial Cell Wall Technology
13/05/05
Bioniche Announces Change in Board of Directors Composition
09/05/05
Bioniche Reports Third Quarter Fiscal 2005 Results
04/05/05
Bioniche to Present at Rodman & Renshaw
03/05/05
Bioniche Reports Third Quarter Results for Fiscal 2005
April 2005
18/04/05
Bioniche Presents Data on Prevention and Management of Urinary Tract Infections Using Cystistat®
March 2005
29/03/05
Bioniche Granted European Patent for MCC in Bladder Cancer
22/03/05
Bioniche Presents Further Data on Mycobacterial Cell Wall-DNA Complex (MCC) at European Association of Urology 20th Congress
14/03/05
Further Research Studies Support E. coli Cattle Vaccine Efficacy
07/03/05
Research Shows Promise for Easy, Effective Management of Sow Breeding
February 2005
10/02/05
Bioniche Reports Second Quarter Fiscal 2005 Results
09/02/05
Bioniche Reports Second Quarter Results for Fiscal 2005
January 2005
28/01/05
Bioniche to Submit Additional Safety Data for its E. coli Vaccine
21/01/05
Bioniche Receives Authorization to Market Folltropin®-V in Additional EU Countries
December 2004
23/12/04
Bioniche Animal Health Appoints New Leaders of European and Australian/Asian Operations
06/12/04
Senior Personnel Change at Bioniche
03/12/04
Livestock Revolution in Global Agriculture
November 2004
29/11/04
New Treatment for Equine Endometritis Given USDA Approval
22/11/04
FDA Approves Bioniche Pharma ANDA for Sotradecol Injection for the Treatment of Varicose Veins
18/11/04
New Data Confirms Unique Anticancer Activity Profile
09/11/04
Bioniche Discusses Further Details of the Phase III Clinical Trial with Urocidin for the Treatment of Bladder Cancer
09/11/04
Bioniche Revenues Increase in First Quarter of Fiscal 2005
08/11/04
New Studies Demonstrate Anti-Cancer Activity of Bioniche Technology Against Canine Cancer
04/11/04
Bioniche Reports First Quarter Results for Fiscal 2005
October 2004
28/10/04
Investment in Bioniche Life Sciences Inc.The Solidarity Fund QFL will invest $10 M and the Bio-Food Investment Fund $2 Mac
20/10/04
Bioniche Annual Report Correction
15/10/04
Industrial Research Chairs in Food Safety Filled
06/10/04
Bioniche Expands its Intellectual Property Portfolio
September 2004
23/09/04
Bioniche Presents Data on Cystistat and Launches Product Web Site at Inaugural Multinational Interstitial Cystitis Association Annual Meeting
21/09/04
Bioniche Reports Year-End Fiscal 2004 Results
20/09/04
Bioniche Appoints a Chief Operating Officer
15/09/04
Bioniche Reports Year-End Fiscal 2004 Results
August 2004
26/08/04
Bioniche Ranked Among the Top 100 Global Biotechnology Companies by Med Ad News
06/08/04
Mycobacterial Cell Wall Formulation Shows Promise in Treating Equine Endometritis
03/08/04
Bomac Laboratories Ltd. to Distribute Bioniche Cue-Mate® Technology in New Zealand
July 2004
22/07/04
Bioniche Presents Pre-Clinical Data on Anti-Cancer Agents and Immunomodulatory Molecules at International Congress of Immunology
June 2004
21/06/04
Bioniche Commences Sales of Cue-Mate® Animal Reproductive Technology in Australian Cattle Market
18/06/04
Bioniche Receives Approval For New Animal Health Product Indication
14/06/04
Pharmacoeconomic Study into Use of Suplasyn® Demonstrates Reduced Pain and Cost-Effectiveness in Treatment of Patients with Osteoarthritis of the Knee
14/06/04
Bioniche Serves Community Needs Through New Pet Loss Program
10/06/04
Bioniche Presents Positive Data on Anti-Cancer Activity of MCC at 22nd Annual Meeting of American College of Veterinary Internal Medicine
08/06/04
Bioniche Ranked Among Canada’s Top 100 Fastest-Growing Companies by PROFIT Magazine
01/06/04
Bioniche Retains The Anne McBride Company Inc.
May 2004
21/05/04
Bioniche’s Pharmaceutical Business Unit Raises 10.8 Million Euro for Expansion of Manufacturing Facilities
20/05/04
Bioniche Presents Bladder Cancer Clinical Trial and Research Data to American Urological Association Annual Meeting
14/05/04
Bioniche Reports Third Quarter Fiscal 2004 Results
12/05/04
Bioniche Reports Third Quarter Fiscal 2004 Results Web Cast
12/05/04
Bioniche E. coli 0157 Vaccine Shows Further Promise
April 2004
19/04/04
Bioniche Acquires Cue-Mate® Reproductive Technology From Pfizer
March 2004
29/03/04
Bioniche Announces Results of Phase I Prostate Cancer Study
February 2004
17/02/04
Bioniche Life Sciences Completes $10,000,000 Financing
13/02/04
Bioniche Reports Second Quarter 2004 Financial Results
05/02/04
Bioniche Enters Into Agreement For $10,000,000 Financing
January 2004
10/01/04
Bioniche Life Sciences and AB Technology Sign Purchase Agreement
|
